IRVINE, Calif., Feb. 13 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. , today announced it will present at Roth Capital Partners 2007 OC Growth Conference at 8:00 a.m. Pacific Time on Tuesday, February 20, at the Ritz Carlton Laguna.
ISTA’s Chief Financial Officer and Vice President of Corporate Development, Lauren Silvernail, will provide an update on the Company’s commercial and clinical progress. To access the live audio broadcast or the subsequent archived recording log onto http://www.istavision.com. Please connect to the website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.
ABOUT ISTA PHARMACEUTICALS
ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA’s products and product candidates addressing the $3.2 billion U.S. prescription ophthalmic industry include therapies for allergy, dry eye, vitreous hemorrhage, diabetic retinopathy, hyphema, glaucoma, ocular pain, and inflammation. The Company currently markets three products and is developing a strong product pipeline to fuel future growth and market share. The Company’s product development and commercialization strategy is to launch a new product every 12 to 18 months, thereby continuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals’ website at http://www.istavision.com.
ISTA Pharmaceuticals, Inc.
CONTACT: Vince Anido, ISTA Pharmaceuticals, +1-949-788-5311,vanido@istavision.com, or Lauren Silvernail, ISTA Pharmaceuticals,+1-949-788-5302, lsilvernail@istavision.com; or Jason Farber (Media),jfarber@burnsmc.com, or Juliane Snowden-Andrew (Investors),jsnowden-andrew@burnsmc.com, both of Burns McClellan, +1-212-213-0006
Web site: http://www.istavision.com/
